This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Toronto directory, so their publications, courses and email address may be missing. Find their university profile.
Latest funding
- $748,990
A randomized phase II study of ramucirumab and paclitaxel +/- zanidatamab in HER2 overexpressing advanced gastroesophageal adenocarcinoma
CIHR · 2022 · Principal investigator
- $2,995,962
A randomized phase II study of ramucirumab and paclitaxel +/- zanidatamab in HER2 overexpressing advanced gastroesophageal adenocarcinoma
CIHR · 2022 · Principal investigator
A randomized phase II study of ramucirumab and paclitaxel +/- zanidatamab in HER2 overexpressing advanced gastroesophageal adenocarcinoma
Principal investigators: Elimova, Elena; Goodwin, Rachel A; Lim, Howard; O'Callaghan, Christopher J; Tu, Dongsheng
Keywords: Clinical Trial; Gastroesophageal Cancer; Her 2 Positive
A randomized phase II study of ramucirumab and paclitaxel +/- zanidatamab in HER2 overexpressing advanced gastroesophageal adenocarcinoma
Principal investigators: Elimova, Elena; Goodwin, Rachel A; Lim, Howard; O'Callaghan, Christopher J; Tu, Dongsheng
Keywords: Clinical Trial; Gastroesophageal Cancer; Her 2 Positive
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.